A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Sorafenib

Sorafenib 200mg po daily

DRUG

Bevacizumab

"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"

OTHER

Imaging

Imaging every third cycle

Trial Locations (10)

44106

Ireland Cancer Center - University Hospitals of Cleveland, Cleveland

46202

Indiana University Simon Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47303

Medical Consultants, P.C., Muncie

47714

Oncology Hematology Associates of SW Indiana, Evansville

47904

Arnett Cancer Care, Lafayette

47905

Horizon Oncology Center, Lafayette

61401

Medical & Surgical Specialists, LLC, Galesburg

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Bayer

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Hoosier Cancer Research Network

OTHER